Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 2Withdrawn 1Unknown 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 1

Conditions

Breast Neoplasms 10Leukemia, Lymphocytic, Chronic, B-Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Mantle-Cell 6Lymphoma, B-Cell, Marginal Zone 6Unspecified Adult Solid Tumor, Protocol Specific 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Colorectal Neoplasms 5Waldenstrom Macroglobulinemia 4Rectal Neoplasms 4Pancreatic Neoplasms 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Extranodal NK-T-Cell 4Lymphoma 4Leukemia, Prolymphocytic 4Leukemia, Myeloid, Acute 4Leukemia 4Hodgkin Disease 4Congenital Abnormalities 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Burkitt Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Sezary Syndrome 3Neoplasms 3Mycosis Fungoides 3

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Pharmacogenomic Testing × Clear all
NCT01015833 2022-08-04

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

National Cancer Institute (NCI)

Phase 3 Completed
356 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT00654160 2017-05-25

Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer

Mayo Clinic

Phase 1 Completed
7 enrolled
GastrointestinalSarcoma

Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT01324076 2011-05-13

Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 3 Unknown
412 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡